The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tolerability and efficacy of a biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin regimen (TFOX) in previously advanced metastatic gastric and oesogastric junction (AGC) adenocarcinoma.
Simon Pernot
No relevant relationships to disclose
Emmanuel Mitry
No relevant relationships to disclose
Emmanuelle Samalin
No relevant relationships to disclose
Laetitia Dahan
No relevant relationships to disclose
Hajer Turki
No relevant relationships to disclose
Thibault Mazard
No relevant relationships to disclose
Marc Ychou
No relevant relationships to disclose
Jean Francois Seitz
No relevant relationships to disclose
Philippe Rougier
No relevant relationships to disclose
Julien Taïeb
No relevant relationships to disclose